Drugs / GNX80
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05400395 | Sep 2022 → Mar 2024 | intermittent vascular claudication | SK Chemicals Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNX80 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05400395 ↗ |
| Route | Oral | “GNX80 oral intake(BID) for 24 weeks” NCT05400395 ↗ |